Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Gil Harmon

Hematology | Oncology
Gundersen Health System
Gundersen Lutheran Medical Center Inc
710 Denton St, 
La Crosse, WI 
Offers Telehealth

Experienced in WT1-Related Wilms Tumor Syndromes
Gundersen Health System
Gundersen Lutheran Medical Center Inc
710 Denton St, 
La Crosse, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Gil Harmon is a Hematologist and an Oncologist in La Crosse, Wisconsin. Dr. Harmon is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Cervical Cancer, Testicular Yolk Sac Tumor, Ovarian Carcinosarcoma, and Virilizing Ovarian Tumor.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in WI
Hospital Affiliations
Gundersen Lutheran Medical Center
Tomah Memorial Hospital
Veterans Memorial Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Icare Independent Care Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Independent Health
  • EPO
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Quartz
  • HMO
  • POS
  • PPO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

GUNDERSEN LUTHERAN MEDICAL CENTER INC
710 Denton St, La Crosse, WI 54601
Call: 608-782-7300
Other Locations
GUNDERSEN LUTHERAN MEDICAL CENTER INC
2575 S 7th St, Bethany Riverside, La Crosse, WI 54601
Call: 608-775-8200

Additional Areas of Focus

Dr. Harmon has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


5 Clinical Trials

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cediranib Maleate, Durvalumab, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Other, Procedure, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
View 4 Less Clinical Trials

4 Total Publications

Gemcitabine combination therapies induce apoptosis in uterine carcinosarcoma patient-derived organoids.
Gemcitabine combination therapies induce apoptosis in uterine carcinosarcoma patient-derived organoids.
Journal: Frontiers in oncology
Published: January 10, 2024
View All 4 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Hamid Emamekhoo
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Hamid Emamekhoo
Hematology Oncology | Hematology | Oncology

University Of Wisconsin Medical Foundation Inc

1040 Division St, 
Mauston, WI 
 (58.4 miles away)
608-847-7355
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Hamid Emamekhoo is a Hematologist Oncology specialist and a Hematologist in Mauston, Wisconsin. Dr. Emamekhoo is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Urothelial Cancer, Nephrectomy, and Tissue Biopsy. Dr. Emamekhoo is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. David Marinier
Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. David Marinier
Hematology | Oncology

Gundersen Clinic Ltd

123 Se 5th Ave, 
Spring Grove, MN 
 (25.1 miles away)
507-498-3302
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Marinier is a Hematologist and an Oncologist in Spring Grove, Minnesota. Dr. Marinier is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, Colorectal Cancer, and Lynch Syndrome.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Anna C. Jones
Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Anna C. Jones
Hematology | Oncology

Mayo Clinic Health System-Southwest Wisconsin Region Inc

800 W Ave S, 
La Crosse, WI 
 (1.0 miles away)
608-785-0940
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anna Jones is a Hematologist and an Oncologist in La Crosse, Wisconsin. Dr. Jones is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Adult Soft Tissue Sarcoma, Colorectal Cancer, Familial Colorectal Cancer, and Muscle Invasive Bladder Cancer. Dr. Jones is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Harmon's expertise for a condition
ConditionClose
    • Distinguished
    • Cervical Cancer
      Dr. Harmon is
      Distinguished
      . Learn about Cervical Cancer.
      See more Cervical Cancer experts
    • Ovarian Carcinosarcoma
      Dr. Harmon is
      Distinguished
      . Learn about Ovarian Carcinosarcoma.
      See more Ovarian Carcinosarcoma experts
    • Sertoli-Leydig Cell Tumor
      Dr. Harmon is
      Distinguished
      . Learn about Sertoli-Leydig Cell Tumor.
      See more Sertoli-Leydig Cell Tumor experts
    • Testicular Yolk Sac Tumor
      Dr. Harmon is
      Distinguished
      . Learn about Testicular Yolk Sac Tumor.
      See more Testicular Yolk Sac Tumor experts
    • Virilizing Ovarian Tumor
      Dr. Harmon is
      Distinguished
      . Learn about Virilizing Ovarian Tumor.
      See more Virilizing Ovarian Tumor experts
    • Advanced
    • Adult Soft Tissue Sarcoma
      Dr. Harmon is
      Advanced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Colorectal Cancer
      Dr. Harmon is
      Advanced
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    • Endometrial Cancer
      Dr. Harmon is
      Advanced
      . Learn about Endometrial Cancer.
      See more Endometrial Cancer experts
    • Familial Colorectal Cancer
      Dr. Harmon is
      Advanced
      . Learn about Familial Colorectal Cancer.
      See more Familial Colorectal Cancer experts
    • Familial Prostate Cancer
      Dr. Harmon is
      Advanced
      . Learn about Familial Prostate Cancer.
      See more Familial Prostate Cancer experts
    • Hodgkin Lymphoma
      Dr. Harmon is
      Advanced
      . Learn about Hodgkin Lymphoma.
      See more Hodgkin Lymphoma experts
    View All 15 Advanced Conditions
    • Experienced
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Harmon is
      Experienced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Astrocytoma
      Dr. Harmon is
      Experienced
      . Learn about Astrocytoma.
      See more Astrocytoma experts
    • Atypical Teratoid Rhabdoid Tumor (ATRT)
      Dr. Harmon is
      Experienced
      . Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
      See more Atypical Teratoid Rhabdoid Tumor (ATRT) experts
    • Bladder Cancer
      Dr. Harmon is
      Experienced
      . Learn about Bladder Cancer.
      See more Bladder Cancer experts
    • Brain Tumor
      Dr. Harmon is
      Experienced
      . Learn about Brain Tumor.
      See more Brain Tumor experts
    • Breast Cancer in Men
      Dr. Harmon is
      Experienced
      . Learn about Breast Cancer in Men.
      See more Breast Cancer in Men experts
    View All 49 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved